Loading...
Docoh

Vir Biotechnology (VIR)

Utility
Coronavirus Irna Compositions and Methods of Use Thereof
28 Apr 22
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome.
Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp
Filed: 10 Nov 21
Utility
Combination HBV Therapy
24 Feb 22
The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use.
Anna Bakardjiev, Phillip S. Pang, Davide Corti
Filed: 19 Dec 19
Utility
Engineered Microorganisms and Methods of Making and Using Same
3 Feb 22
The present disclosure provides for engineered microorganisms and methods of making and using same.
Gautam DANTAS, Suryang KWAK, Herbert VIRGIN
Filed: 20 Sep 19
Utility
Coronavirus iRNA compositions and methods of use thereof
28 Dec 21
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome.
Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp
Filed: 17 May 21
Utility
Antibodies Against SARS-COV-2 and Methods of Using the Same
2 Dec 21
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection.
Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
Filed: 23 Jul 21
Utility
Antibodies against SARS-CoV-2 and methods of using the same
9 Nov 21
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection.
Davide Corti, Katja Fink, Martina Beltramello, Elisabetta Cameroni, Dora Pinto, Gyorgy Snell, Florian A. Lempp, Amalio Telenti
Filed: 25 Feb 21
Utility
Antibodies Against SARS-COV-2 and Methods of Using the Same
26 Aug 21
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection.
Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
Filed: 25 Feb 21
Utility
Hiv Vaccines Comprising One or More Population Episensus Antigens
18 Feb 21
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach.
Eric Bruening, Klaus Frueh, Louis Picker, Bette T.M. Korber, James Theiler, Emily Marshall
Filed: 31 Aug 20
Utility
Hiv Vaccines Comprising One or More Population Episensus Antigens
18 Feb 21
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach.
Eric Bruening, Klaus Frueh, Louis Picker, Bette T.M. Korber, James Theiler, Emily Marshall
Filed: 31 Aug 20
Utility
HIV vaccines comprising one or more population episensus antigens
19 Jan 21
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach.
Eric Bruening, Klaus Frueh, Louis Picker, Bette T. M. Korber, James Theiler, Emily Marshall
Filed: 5 Oct 15
  • 1
Patents are sorted by USPTO publication date, most recent first